Minimally invasive sclera crosslinking device as well as use method and application thereof

Abstract

The invention relates to the technical field of eye medical instruments, in particular to a minimally invasive sclera cross-linking device and a using method and application thereof.The minimally invasive sclera cross-linking device comprises a main body and an operating handle, the main body is sequentially provided with a cross-linking cavity, an annular adsorption cavity and an adsorption skirt edge from inside to outside, and a pressure bag cavity and a cross-linking agent cavity are sequentially arranged in the cross-linking cavity from top to bottom; a metal film electrode is arranged on a top cover in the pressure bag cavity, a position indicating lamp and a cross-linking light source are arranged on the metal film electrode, one end of the cross-linking agent cavity is communicated with a cross-linking agent pipeline and a cleaning pipeline, the pressure bag cavity is communicated with a pressure applying pipeline, and the adsorption annular cavity is communicated with an air exhaust pipeline. The cross-linking agent pipeline, the cleaning pipeline, the pressure applying pipeline and the air exhaust pipeline are all located in the operating handle. By the adoption of the structure, pressure is applied to the sclera, crosslinking is conducted, the deformation resistance of the sclera is improved through crosslinking, the curvature of the sclera can be reduced, and then the axis of the eye is shortened or the axis of the eye is prevented from being further prolonged.

Description

Technical Field

[0001] The present invention relates to the technical field of ocular medical devices, and in particular to a minimally invasive scleral cross-linking device and a use method and application thereof. Background Art

[0002] Pathological myopia is the most common blinding eye disease. Fundus changes and posterior scleral staphyloma are the main features of pathological myopia. There is currently no effective treatment for pathological myopia. High myopia can develop into pathological myopia, the main feature of which is the abnormal growth of the axial length. When the axial length grows to a certain extent, the sclera will become thinner and its ability to resist deformation will also decrease, which can lead to a series of lesions in the fundus structure. Scleral thinning mainly occurs in the posterior pole. By cross-linking the posterior pole of the sclera, the degree of interconnection between collagen fibers in the sclera can be increased, thereby increasing the mechanical strength and hardness of the sclera and preventing further elongation of the axial length. This has been fully verified in animal experiments. Therefore, scleral cross-linking is expected to become a clinical method for treating pathological myopia.

[0003] At present, the experimental methods of scleral cross-linking include riboflavin plus ultraviolet light cross-linking and chemical cross-linking. Photochemical cross-linking is to first apply riboflavin to the tissue, wait for it to penetrate into the tissue for a certain period of time, and then use ultraviolet light with a wavelength of about 365nm to make riboflavin (photosensitizer) produce reactive oxygen and react with the amino groups of scleral collagen fibers to produce cross-linking bonds, thereby increasing the deformation resistance of collagen fibers. When this method is used for posterior scleral cross-linking, in order for riboflavin and ultraviolet light to reach the area to be cross-linked, the extraocular muscles need to be cut and the posterior pole of the eyeball to be cross-linked is everted and exposed to the front. However, this method is traumatic, prone to infection, and has poor patient acceptance. In addition, it may cause surgical strabismus due to improper suturing of the extraocular muscles. Therefore, it is of great significance to develop a minimally invasive scleral cross-linking device with the functions of drug delivery and ultraviolet light introduction. Summary of the invention

[0004] The purpose of the present invention is to provide a minimally invasive sclera cross-linking device and a method of use and application. By applying pressure to the sclera in the cross-linking chamber, the tensile strain of the sclera, which is originally in a stretched state under the action of intraocular pressure, is reduced or even converted into a compressive strain, thereby achieving not only improving the deformation resistance of the sclera through cross-linking, but also reducing its curvature, thereby shortening the eye axis or preventing the eye axis from further elongation.

[0005] To achieve the above-mentioned objectives, the present invention provides a minimally invasive scleral cross-linking device, comprising a main body and an operating handle, wherein the main body is provided with a cross-linking chamber, an adsorption annular chamber and an adsorption skirt from the inside to the outside, wherein a pressure bag chamber and a cross-linking agent chamber are provided from top to bottom, wherein a metal film electrode is provided at the top cover of the pressure bag chamber, wherein a position indicator light and a cross-linking light source are provided on the metal film electrode, wherein one end of the cross-linking agent chamber is connected to a cross-linking agent pipeline and a cleaning pipeline, the pressure bag chamber is connected to a pressure pipeline, the adsorption annular chamber is connected to an exhaust pipeline, and the cross-linking agent pipeline, the cleaning pipeline, the pressure pipeline and the exhaust pipeline are all located in the operating handle.

[0006] Preferably, the position indicator light is arranged at the center of the metal film electrode and at one end away from the cross-linking agent pipeline, and cross-linking light sources are arranged around the position indicator light.

[0007] Preferably, the pressure capsule cavity and the cross-linking agent cavity are separated by a transparent capsule membrane, the transparent capsule membrane is made of a transparent material with deformation ability and good biocompatibility, and the thickness of the transparent capsule membrane is 0.5±0.45 mm.

[0008] Preferably, an elastic transparent capsule is provided in the pressure capsule cavity, and the elastic transparent capsule is connected to the pressure pipe. The elastic transparent capsule is made of an elastic material with low ultraviolet extinction coefficient, transparency, and large deformation, and the thickness of the elastic transparent capsule is 0.5 mm ± 0.45 mm. After the separated elastic transparent capsule is expanded under pressure, it can be close to the side wall of the cross-linking chamber at the pressure capsule cavity, completely separating the pressure capsule cavity and the cross-linking agent cavity.

[0009] Preferably, the cross-linking agent pipeline, the cleaning pipeline and the pressure pipeline all pass through the adsorption annular cavity and are connected with the cross-linking chamber.

[0010] Preferably, the vertical section of the cross-linking chamber is an arc-shaped structure, and the cross-section of the outer wall of the cross-linking chamber is a rectangular structure. When it is an oblong shape, the width of the arc band is 3-8 mm, and when it is a combination of a rectangle and an oblong shape, the widest part is 3-8 mm. The horizontal orthographic projection of the inner wall of the cross-linking chamber is one or more of a rectangle and an oblong shape.

[0011] Preferably, the adsorption annular cavity is an annular groove structure outside the cross-linking cavity, the cross-section of the outer wall of the adsorption annular cavity is one or more of rectangular and oblong, and the thickness of the outer wall of the adsorption annular cavity is 0.3-2.5 mm.

[0012] More preferably, the shape of the adsorption annular cavity is U-shaped, closed ring-shaped or other circular arc strip-shaped shapes in space.

[0013] Preferably, the radius of the main body is 8-14 mm, the total length is 15-40 mm, the height is 5±4 mm, and the thickness of the top cover is 1.5±1.2 mm.

[0014] Preferably, the cross-linking light source includes one or more of ultraviolet light and blue light.

[0015] Preferably, the width of the adsorption skirt is 0.2-1.8 mm, and the thickness is 0.2-1 mm.

[0016] Preferably, the thickness of the metal film electrode is 0.02-0.5 mm.

[0017] Preferably, the total light intensity of the crosslinking light source is 3-90 mW / cm 2 .

[0018] The method for using the above-mentioned minimally invasive scleral cross-linking device comprises the following steps: S1. Hold the operating handle and slide the main body from the incision at the fornix conjunctiva along the surface of the sclera into the part of the posterior pole of the eyeball to be cross-linked; S2. Observe the position of the position indicator from the pupil to adjust the position of the main body relative to the eyeball, and pump air outward through the air pumping pipe, so that the suction ring cavity is adsorbed on the eyeball to fix the main body; S3, the cross-linking agent enters the cross-linking agent cavity through the cross-linking agent pipeline and is dripped on the surface of the sclera, and the pressure gas / liquid is introduced into the pressure capsule cavity through the pressure pipeline, so that the transparent capsule presses the sclera downward; S4, selecting whether to turn on the cross-linking light source to irradiate the cross-linking agent on the surface of the sclera, waiting for the cross-linking agent to cross-link until the cross-linking is completed, and releasing the pressure gas / liquid; S5, sucking out the cross-linking agent remaining in the cross-linking agent cavity through the cleaning pipeline, and then cleaning with physiological saline; S6. Open the vacuum pipe to release the negative pressure in the adsorption annular cavity and take out the main body.

[0019] Preferably, in S3, the transparent capsule presses the convex sclera down to make it flat or concave downward.

[0020] Preferably, in S4, during the cross-linking process of the cross-linking agent, oxygen can be introduced into the cross-linking agent cavity through the cross-linking agent pipeline.

[0021] A minimally invasive scleral cross-linking device is used in the treatment of high myopia, progressive myopia, pathological myopia and posterior scleral staphyloma.

[0022] Therefore, the present invention adopts a minimally invasive scleral cross-linking device and a method and application of the above structure, and its beneficial effects are: 1. The sclera cross-linking device provided by the present invention adopts an integrated four-pipe main structure with separated inner and outer cavities. A negative pressure state can be formed by vacuuming through the vacuum channel. Since the adsorption annular cavity and the adsorption skirt cooperate with each other, the frame of the adsorption annular cavity can fit closely with the sclera surface to form a long closed chamber, thereby preventing the cross-linking agent from overflowing to the non-cross-linking area of ​​the eyeball; 2. When the cross-linked chamber provided by the present invention cooperates with the pressure channel to compress the sclera, the originally spherical sclera can be flattened or indented, so that the tensile strain of the sclera, which is originally in a stretched and expanded state under the action of intraocular pressure, is reduced or even reversed into a compressive strain, thereby achieving the goal of improving the deformation resistance of the sclera through cross-linking, while reducing the convexity of the sclera, shortening the axial length of the eye, and correcting the degree of myopia; 3. The main body provided by the present invention is made of thermoplastic polyurethane or other materials with certain flexibility and elasticity and stable mechanical properties. The device can be placed in various parts of the sclera (including the posterior pole) without damaging the eyeball and intraocular tissues by only cutting a small incision at the conjunctiva of the fornix without cutting the extraocular muscles or everting the eyeball.

[0023] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is a bottom-up schematic diagram of a minimally invasive scleral cross-linking device of the present invention (the transparent capsule membrane / elastic transparent capsule, metal film electrode, cross-linking light source and position indicator light are not shown); Figure 2 is a top view of a minimally invasive scleral cross-linking device of the present invention; Figure 3 It is a bottom-up cross-sectional schematic diagram of a minimally invasive scleral cross-linking device of the present invention; Figure 4 is a side cross-sectional view of a minimally invasive scleral cross-linking device in Example 1 of the present invention; Figure 5 is a front cross-sectional view of a minimally invasive scleral cross-linking device in Example 1 of the present invention; Figure 6 This is a front view schematic diagram of a minimally invasive scleral cross-linking device in Example 1 of the present invention connected to an eyeball when in use; Figure 7 It is a top view schematic diagram of a minimally invasive scleral cross-linking device (the main body is rectangular when viewed from above) of the present invention and its connection with the eyeball when in use; Figure 8 It is a top view schematic diagram of a minimally invasive scleral cross-linking device (the main body is an oblong shape when viewed from above) of the present invention when connected to an eyeball during use; Fig. 9 It is a schematic diagram of the connection between the elastic transparent bag and the pressure pipe in Example 2 of the present invention.

[0025] Reference numerals: 1. Adsorption annular cavity; 2. Cross-linking chamber; 3. Top cover; 4. Adsorption skirt; 5. Cross-linking agent pipeline; 6. Pressure pipeline; 7. Cleaning pipeline; 8. Exhaust pipeline; 9. Transparent capsule membrane; 10. Metal film electrode; 11. Cross-linking light source; 12. Position indicator light; 13. Cross-linking agent cavity; 14. Pressure capsule cavity; 15. Inner wall of adsorption annular cavity; 16. Outer wall of adsorption annular cavity; 17. Wire tube; 18. Chamfer. DETAILED DESCRIPTION

[0026] The present invention is further described below in conjunction with the accompanying drawings and embodiments. Unless otherwise defined, the technical terms or scientific terms used in the present invention should be the common meanings understood by people with ordinary skills in the field to which the present invention belongs. The above-mentioned features or features mentioned in the specific examples mentioned in the present invention can be combined arbitrarily, and these specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0027] Example 1 like Figure 1-Figure 5 As shown, the present invention provides a minimally invasive scleral cross-linking device, including a main body and an operating handle. The main body is provided with a cross-linking chamber 2, an adsorption annular chamber 1 and an adsorption skirt 4 from the inside to the outside, and a transparent capsule 9 is provided in the cross-linking chamber 2. The cross-linking chamber 2 is provided with a pressure capsule 14 between the transparent capsule 9 and the top cover 3, and a metal film electrode 10 is provided at the top cover 3 in the pressure capsule 14, and a position indicator 12 and a cross-linking light source 11 are provided on the metal film electrode 10. The cross-linking chamber 2 is provided with a cross-linking agent chamber 13 below the transparent capsule 9, and one end of the cross-linking agent chamber 13 is connected to the cross-linking agent pipeline 5 and the cleaning pipeline 7. The pressure capsule chamber 14 is connected to the pressure pipeline 6, and the adsorption annular chamber 1 is connected to the exhaust pipeline 8. The cross-linking agent pipeline 5, the cleaning pipeline 7, the pressure pipeline 6 and the exhaust pipeline 8 are all located in the operating handle.

[0028] The cross-linking device can be integrally formed or assembled together after being formed separately. The manufacturing materials can include but are not limited to other elastic materials with good ductility, good biocompatibility and no biotoxicity, including polyurethane elastomer material DPI8400. In this embodiment, the horizontal projection of the main body in the cross-linking device is an oblong. The contact point between the main body and the sclera is coated with a coating, and the coating uses a hydrogel material with good biocompatibility and no biotoxicity. The setting of the exhaust pipe 8 is used to extract the gas in the adsorption annular cavity 1 through the exhaust pipe 8, and a negative pressure is formed in the adsorption annular cavity 1. The adsorption annular cavity 1 and the adsorption skirt 4 are in adsorption contact with the eyeball, thereby fixing the main body on the eyeball. The setting of the adsorption annular cavity 1 and the adsorption skirt 4 can also isolate the cross-linking agent in the cross-linking agent cavity 13 from other parts of the eyeball, preventing the cross-linking agent from entering the adsorption annular cavity 1 or the eyeball outside the main body.

[0029] The power supply wires of the metal film electrode 10, the cross-linking light source 11 and the position indicator light 12 are arranged in the wire tube 17 of the operating handle, and the wire tube 17 is introduced into the outside of the device through the inner and outer walls of the adsorption annular cavity 1 and connected to the power supply. The setting of the position indicator light 12 is convenient for the user to locate the position of the main body according to the position indicator light 12, so as to place the main body at the designated position of the eyeball. The cross-linking agent enters the cross-linking agent cavity 13 through the cross-linking agent pipeline 5, contacts the eyeball and penetrates into the sclera. During the cross-linking process of the cross-linking agent, oxygen can be introduced into the cross-linking agent cavity 13 through the cross-linking agent pipeline 5. Choose whether to turn on the cross-linking light source 11 to perform light cross-linking operation on the cross-linking agent.

[0030] The pressure pipe 6 is set up, and the pressure gas / liquid enters the pressure capsule cavity 14 through the pressure pipe 6, and presses the transparent capsule membrane 9 downward to deform it, and the transparent capsule membrane 9 presses the sclera downward to make it flat or concave downward. The cleaning pipe 7 is connected with the cross-linking agent cavity 13, and while absorbing the excess cross-linking agent, the eyeball inside the cross-linking agent cavity 13 is cleaned with a cleaning agent to prevent other parts of the sclera and the contents of the eye socket from being affected by the residual cross-linking agent.

[0031] The position indicator light 12 is arranged at the center of the metal film electrode 10 and at one end away from the cross-linking agent pipeline 5, and a cross-linking light source 11 is arranged around the position indicator light 12. The position setting of the position indicator light 12 facilitates the user to determine the position of the main body relative to the eyeball according to the position of the position indicator light 12 observed, so as to place the main body at the designated position of the eyeball.

[0032] The transparent capsule 9 is made of a transparent material with good biocompatibility and good deformability, and the thickness of the transparent capsule 9 is 0.5±0.45 mm. The transparent capsule 9 can be in contact with the sclera under the action of pressurized gas / liquid, and the cross-linking light source 11 can also irradiate the surface of the sclera through the transparent capsule 9. When the transparent capsule 9 is not provided, only pressurized gas is used to apply pressure. After the pressure is applied, the sclera to be cross-linked becomes flat or inward under the pressure.

[0033] The cross-linking agent pipeline 5, the cleaning pipeline 7 and the pressure pipeline 6 all penetrate the adsorption annular cavity 1 and communicate with the cross-linking chamber 2. The inner diameters of the cross-linking agent pipeline 5, the cleaning pipeline 7, the exhaust pipeline 8 and the pressure pipeline 6 can be varied within 0.2-3 mm as required, and the pipeline wall thickness is 0.6±0.4 mm, and the lengths of these pipelines are not limited.

[0034] The vertical section of the cross-linking chamber 2 is an arc-shaped structure, the cross-section of the outer wall of the cross-linking chamber 2 is a rectangular structure, and the horizontal projection of the inner wall of the cross-linking chamber 2 is a combination of a rectangle and an oblong.

[0035] The cross section of the adsorption annular cavity 1 is one or more of a rectangular and an oblong. When it is an oblong, the arc width is 3-8 mm, and when it is a combination of a rectangular and an oblong, the widest part is 3-8 mm. The thickness of the outer wall 16 of the adsorption annular cavity is 0.3-2.5 mm, and the inner wall 15 of the adsorption annular cavity is the outer wall of the cross-linking chamber 2.

[0036] The shape of the cross-linking chamber 2 and the adsorption annular chamber 1 is set so that the long arc-shaped main body is in close contact with the eyeball and does not fall off, and the cross-linking agent does not overflow from the cross-linking chamber 2.

[0037] The radius of the main body is 8-14 mm, the total length is 15-40 mm, the height is 5± 4 mm, the thickness of the top cover 3 is 1.5±1.2 mm, and the top cover 3 is provided with a chamfer 18 on the outside.

[0038] The cross-linking light source 11 includes one or more of ultraviolet light and blue light.

[0039] The width of the adsorption skirt 4 is 0.2~1.8 mm, and the thickness is 0.2~1 mm.

[0040] The metal film electrode 10 has a thickness of 0.02-0.5 mm and is made of conductive metal.

[0041] The total light intensity of the cross-linking light source 11 is 3-90 mW / cm 2 , the power of position indicator light 12 shall be based on what can be seen clearly from the pupil.

[0042] Example 2 like Fig. 9 As shown, the difference between this embodiment and the embodiment 1 is that an elastic transparent capsule 19 is provided in the pressure capsule cavity 14, and the elastic transparent capsule 19 is connected with the pressure-applying pipeline 6. Pressurized gas / liquid is injected into the elastic transparent capsule 19 through the pressure-applying pipeline 6, and the elastic transparent capsule 19 expands to contact the side wall of the cross-linking chamber 2, completely separating the pressure capsule cavity 14 and the cross-linking agent cavity 13, and at the same time, the elastic transparent capsule 19 presses down the outwardly protruding sclera to make it flat or concave downward.

[0043] Example 3 A method for using a minimally invasive scleral cross-linking device in Example 1 comprises the following steps: S1, such as Figure 6 As shown, hold the operating handle, and slide the main body from a 5-10 mm incision in the fornix conjunctiva along the surface of the sclera into the posterior pole of the eyeball to be cross-linked.

[0044] S2, observe the position of the position indicator light 12 from the pupil to adjust the position of the main body relative to the eyeball, so that the adsorption skirt 4 contacts and covers the outer edge of the part of the sclera to be cross-linked. Figure 8As shown, air is sucked outwards through the air suction pipe 8, and the annular cavity 1 is adsorbed to form negative pressure to be adsorbed on the eyeball, thereby fixing the main body.

[0045] S3. The cross-linking agent riboflavin enters the cross-linking agent cavity 13 through the cross-linking agent pipeline 5 and is dripped on the surface of the sclera. The pressure gas / liquid is introduced into the pressure capsule cavity 14 through the pressure pipeline 6, so that the transparent capsule membrane 9 presses the sclera downward, and the transparent capsule membrane 9 presses the protruding sclera downward to be flat or concave.

[0046] S4, turn on the cross-linking light source 11 ultraviolet light to irradiate the cross-linking agent riboflavin on the surface of the sclera, using 3 mW / cm 2 The ultraviolet light irradiation time is about 30 minutes, wait for the cross-linking agent riboflavin to cross-link until the cross-linking is completed, turn off the cross-linking light source 11 and release the pressure gas / liquid. During the cross-linking process of the cross-linking agent, oxygen can be introduced into the cross-linking agent cavity 13 through the cross-linking agent pipeline 5 to further accelerate the photochemical cross-linking reaction speed, increase the cross-linking effect, and shorten the ultraviolet light irradiation time.

[0047] S5. Suck out the cross-linking agent remaining in the cross-linking agent cavity 13 through the cleaning pipe 7, and then clean it with physiological saline.

[0048] S6. Open the exhaust pipe 8 to release the negative pressure in the adsorption annular chamber 1 and take out the main body.

[0049] Example 4 The difference between this embodiment and the minimally invasive scleral cross-linking device in embodiment 1 is that the main body is rectangular in top view, and the rest is the same as embodiment 1. The method of using the minimally invasive scleral cross-linking device in this embodiment includes the following steps: S1. Hold the operating handle and slide the main body into the posterior pole of the eyeball to be cross-linked along the surface of the sclera through a 5-10 mm incision in the fornix conjunctiva.

[0050] S2, observe the position of the position indicator light 12 from the pupil to adjust the position of the main body relative to the eyeball, so that the adsorption skirt 4 contacts and covers the outer edge of the part of the sclera to be cross-linked, such as Figure 7 The air is sucked outwards through the air suction pipe 8, and the annular cavity 1 is sucked to form a negative pressure to be sucked on the eyeball, thereby fixing the main body.

[0051] S3. The cross-linking agent (genipin or other cross-linking agents) enters the cross-linking agent cavity 13 through the cross-linking agent pipeline 5 and is dripped on the surface of the sclera. The pressure gas / liquid is introduced into the pressure capsule cavity 14 through the pressure pipeline 6, so that the transparent capsule membrane 9 presses the sclera downward, and the transparent capsule membrane 9 presses the protruding sclera downward to be flat or concave.

[0052] S4, waiting for the cross-linking agent to cross-link until the cross-linking is completed, and releasing the pressurized gas / liquid.

[0053] S5. Suck out the cross-linking agent remaining in the cross-linking agent cavity 13 through the cleaning pipe 7, and then clean it with physiological saline.

[0054] S6. Open the exhaust pipe 8 to release the negative pressure in the adsorption annular chamber 1 and take out the main body.

[0055] Example 5 A method for using a minimally invasive scleral cross-linking device in Example 1 comprises the following steps: S1. Hold the operating handle and slide the main body into the posterior pole of the eyeball to be cross-linked along the surface of the sclera through a 5-10 mm incision in the fornix conjunctiva.

[0056] S2. Observe the position of the position indicator light 12 from the pupil to adjust the position of the main body relative to the eyeball, so that the adsorption skirt 4 contacts and covers the outer edge of the part of the sclera to be cross-linked. The air is sucked outward through the air suction pipe 8, and the adsorption annular cavity 1 forms a negative pressure to adsorb on the eyeball to fix the main body.

[0057] S3, the cross-linking agent riboflavin enters the cross-linking agent cavity 13 through the cross-linking agent pipeline 5 and is dripped on the surface of the sclera. The cross-linking agent riboflavin infiltrates the cornea of ​​the eyeball to be cross-linked. At the same time, the metal film electrode 10 is turned on to form a loop power supply with the electrode attached to the eyelid or the front of the eye frame. The riboflavin solution is driven by the current to accelerate the infiltration and penetration into the sclera. The infiltration time can be determined according to the infiltration method (if materials that promote the penetration of riboflavin into the tissue are added, the infiltration time will be shortened), and it usually takes 5-30 minutes. The pressure gas / liquid is introduced into the pressure capsule cavity 14 through the pressure pipeline 6, so that the transparent capsule membrane 9 presses the sclera downward, and the transparent capsule membrane 9 presses the protruding sclera downward to be flat or concave downward.

[0058] S4, turn on the cross-linking light source 11 ultraviolet light to irradiate the cross-linking agent riboflavin on the surface of the sclera, using 3 mW / cm 2 The ultraviolet light irradiation time is about 30 minutes, wait for the cross-linking agent riboflavin to cross-link until the cross-linking is completed, turn off the cross-linking light source 11 and release the pressure gas / liquid. During the cross-linking process of the cross-linking agent, oxygen can be introduced into the cross-linking agent cavity 13 through the cross-linking agent pipeline 5 to further accelerate the photochemical cross-linking reaction speed, increase the cross-linking effect, and shorten the ultraviolet light irradiation time.

[0059] S5. Suck out the cross-linking agent remaining in the cross-linking agent cavity 13 through the cleaning pipe 7, and then clean it with physiological saline.

[0060] S6. Open the exhaust pipe 8 to release the negative pressure in the adsorption annular chamber 1 and take out the main body.

[0061] Therefore, the present invention adopts a minimally invasive sclera cross-linking device, a method of use and an application of the above-mentioned structure, which applies pressure to the sclera in the cross-linking chamber, thereby reducing the tensile strain of the sclera that is originally in a stretched state under the action of intraocular pressure or even converting it into a compressive strain, thereby achieving not only improving the deformation resistance of the sclera through cross-linking, but also reducing its curvature, thereby shortening the eye axis or preventing the eye axis from further elongating.

[0062] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. A minimally invasive scleral cross-linking device, characterized in that: It includes a main body and an operating handle. The main body is provided with a cross-linking chamber, an adsorption annular chamber and an adsorption skirt from the inside to the outside. The cross-linking chamber is provided with a pressure bag chamber and a cross-linking agent chamber from top to bottom. A metal film electrode is provided at the top cover of the pressure bag chamber. A position indicator light and a cross-linking light source are provided on the metal film electrode. One end of the cross-linking agent chamber is connected with a cross-linking agent pipeline and a cleaning pipeline, the pressure bag chamber is connected with a pressure pipeline, the adsorption annular chamber is connected with an exhaust pipeline, and the cross-linking agent pipeline, the cleaning pipeline, the pressure pipeline and the exhaust pipeline are all located in the operating handle.

2. A minimally invasive scleral cross-linking device according to claim 1, characterized in that: The position indicator light is arranged at the center of the metal film electrode and at one end away from the cross-linking agent pipeline, and cross-linking light sources are arranged around the position indicator light.

3. A minimally invasive scleral cross-linking device according to claim 1, characterized in that: The pressure capsule cavity and the cross-linking agent cavity are separated by a transparent capsule membrane. The transparent capsule membrane is made of a transparent material with deformation ability and good biocompatibility. The thickness of the transparent capsule membrane is 0.5±0.45 mm.

4. A minimally invasive scleral cross-linking device according to claim 1, characterized in that: The cross-linking agent pipeline, the cleaning pipeline and the pressure pipeline all penetrate the adsorption annular cavity and are connected with the cross-linking chamber.

5. The minimally invasive scleral cross-linking device according to claim 1, characterized in that: The vertical section of the cross-linking chamber is an arc-shaped structure, the cross-section of the outer wall of the cross-linking chamber is a rectangular structure, and the horizontal projection of the inner wall of the cross-linking chamber is one or more of a rectangle and an oblong.

6. The minimally invasive scleral cross-linking device according to claim 1, characterized in that: The adsorption annular cavity is an annular groove structure outside the cross-linking cavity, and the cross section of the outer wall of the adsorption annular cavity is one or more of a rectangular shape and an oblong shape.

7. The minimally invasive scleral cross-linking device according to claim 1, characterized in that: An elastic transparent bag is arranged in the pressure bag cavity, and the elastic transparent bag is communicated with the pressure pipeline.

8. A method for using a minimally invasive scleral cross-linking device according to any one of claims 1 to 7, characterized in that: The following steps are included: S1. Hold the operating handle and slide the main body from the incision at the fornix conjunctiva along the surface of the sclera into the part to be cross-linked at the posterior pole of the eyeball; S2. Observe the position of the position indicator from the pupil to adjust the position of the main body relative to the eyeball, and pump air outward through the air pumping pipe, so that the suction ring cavity is adsorbed on the eyeball to fix the main body; S3, the cross-linking agent enters the cross-linking agent cavity through the cross-linking agent pipeline and is dripped on the surface of the sclera, and the pressure gas / liquid is introduced into the pressure capsule cavity through the pressure pipeline, so that the transparent capsule membrane or the elastic transparent capsule presses the sclera downward; S4, selecting whether to turn on the cross-linking light source to irradiate the cross-linking agent on the surface of the sclera, waiting for the cross-linking agent to cross-link until the cross-linking is completed, and releasing the pressure gas / liquid; S5, sucking out the cross-linking agent remaining in the cross-linking agent cavity through the cleaning pipeline, and then cleaning with physiological saline; S6. Open the vacuum pipe to release the negative pressure in the adsorption annular cavity and take out the main body.

9. The method for using the minimally invasive scleral cross-linking device according to claim 8, characterized in that: In S3, the transparent capsule or elastic transparent capsule presses the convex sclera down to a flat or concave shape.

10. Use of a minimally invasive scleral cross-linking device according to any one of claims 1 to 7, characterized in that: Used in the treatment of high myopia, progressive myopia, pathological myopia and posterior scleral staphyloma.

Images